Participants with known brain metastases
Participants with known metastases
Participants with known brain metastases should be excluded; screening for brain metastases with head imaging is not required
Participants with > 6 definitive lesions consistent with brain metastases
Known intracranial metastases
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants with known untreated brain metastases are excluded; patients with a history of brain metastases are permitted to enroll if they have been treated, are no longer taking corticosteroids, and have been stable for a minimum of one month on imaging; exceptions for participants with asymptomatic sub-centimeter metastases that, in the opinion of the treating investigator, do not require intervention may be possible following discussion and agreement with the overall principal investigator
Participants with known untreated brain metastases should be excluded from this clinical trial; participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for >= 4 weeks following the last date of treatment are permitted
Participants with known untreated brain metastases should be excluded from this clinical trial; participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for >= 4 weeks following the last date of treatment are permitted
Participants with known untreated brain metastases should be excluded from this clinical trial; participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for at least one month following the end of treatment are permitted.
Participants with known brain metastases should be excluded
Participants with active brain metastases
Have no known metastases
Patients with known brain metastases should be excluded
Subjects with known metastases
Patients with known brain metastases (treated or not) will be excluded
Patients with known MIBG-avid parenchymal brain metastases are excluded
Patients with known brain metastases are excluded
Patients with known metastases are not eligible
Participants with known uncontrolled brain metastases will be excluded from this clinical
Participants with known brain metastases
PHASE II: Participants with known brain metastases should be excluded
Participants with known brain metastases
Participants with known brain metastases
Participants with known brain metastases
Any known metastases
Known presence of metastases
Participants with metastases
Patients with known brain metastases are excluded from this study
Patients with known brain metastases will be excluded
Participants with known brain metastases that are symptomatic and require corticosteroids are excluded
Participants with known brain metastases
Participants with known brain metastases, or any other metastases from cancer
Participants with known uncontrolled brain metastases